nature's tirzepatide reduces food intake and appetite, and affects brain functioning, more than placebo and liraglutide Tirzepatide Complete - Momentum Health

Important topics include: Potential drug interactions between GLP-1 medications and DMARDs Monitoring strategies for both conditions Whether weight loss might improve RA symptoms or treatment response Cardiovascular risk reduction strategies Safety considerations including contraindications (personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2) Patients should not discontinue or modify DMARD therapy based on unproven theories about GLP-1 medications treating RA

doi: 10.1111/dom.15875

These observations indicate the importance of additional investigations of long-term dementia risk

3 Voy has the next strongest evidence base